{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.2","upperLimit":"100","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"It is expected that approximately 20% of the patients will receive cyclophosphamide (CTX) for mobilization and this may influence the PFS. Therefore, in a secondary analysis the 2 year PFS rate will be evaluated among those patients who did not receive CTX.","dispersionType":"90% Confidence Interval","groups":[{"description":"* A treatment cycle is defined as 28 consecutive days.\n* Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months.\n\nNivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and\n\nLenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12\n\nDexamethasone: Oral, Days 1, 8, 15 of cycle 1-6","id":"OG000","title":"Nivolumab, Lenalidomide, Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 Years","title":"Progression Free Survival Rate-Without Cyclophosphamide","type":"SECONDARY","unitOfMeasure":"percentage of participants"}